Chemomab TherapeuticsCMMB
13F holders, Q4 2025 (December 31)14holders +4
6new positions
2sold out
1famous investor
$1.65avg. 13F price*
At the end of Q4 2025, 14 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, up 4 from Q3 2025. 6 opened new positions and 2 sold out. The largest holders were Citadel Advisors ($171K), ADAR1 Capital Management, LLC ($132K) and Ikarian Capital, LLC ($85K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $438K |
| Exits | 2 | $551K |
All 13F filers, Q3 2025 → Q4 2025: 280,166 shares bought and 303,097 shares sold, net −22,931 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Citadel Advisors | 0.00% | New | 103,781 | $171K |
| ADAR1 Capital Management, LLC | 0.01% | New | 80,000 | $132K |
| Ikarian Capital, LLC | 0.01% | Reduce -2.8% | 51,793 | $85K |
| Kestra Private Wealth Services, LLC | 0.00% | New | 51,710 | $85K |
| XTX Topco Ltd | 0.00% | New | 19,013 | $31K |
| Rhumbline Advisers | 0.00% | Add +87.9% | 17,856 | $29K |
| Jane Street Group, LLC | 0.00% | Reduce -27.5% | 15,598 | $26K |
| Virtu Financial LLC | 0.00% | New | 10,933 | $18K |
| BNP Paribas Financial Markets | 0.00% | Add +41.3% | 8,125 | $13K |
| Morgan Stanley | 0.00% | Reduce -95.8% | 3,775 | $6K |
| GAMMA Investing LLC | 0.00% | Add +276.9% | 2,514 | $4K |
| UBS Group AG | 0.00% | Add +2175.8% | 2,253 | $4K |
| SBI Securities Co., Ltd. | 0.00% | No change | 26 | $43 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 2 | $3 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.